Suppr超能文献

二维剪切波弹性成像和点剪切波弹性成像在诊断代谢功能障碍相关脂肪性肝病患者肝纤维化不同阶段中的诊断准确性:一项荟萃分析。

Diagnostic accuracy of two-dimensional shear wave elastography and point shear wave elastography in identifying different stages of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: A meta-analysis.

作者信息

Xu Xiangyi, Zhang Yiqing, Zhu Qiwei, Xie Yuchen, Zhou Yuanyuan, Dong Bingtian, Zhang Chaoxue

机构信息

Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

出版信息

Biomol Biomed. 2025 Mar 7;25(4):810-821. doi: 10.17305/bb.2024.11577.

Abstract

To assess the diagnostic accuracy of two-dimensional shear wave elastography (2-D SWE) and point shear wave elastography (pSWE) in detecting liver fibrosis stages in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), a comprehensive search was conducted across four databases up to February 9, 2024. A bivariate random-effects model was used to analyze the diagnostic accuracy of the methods. After screening, 13 studies involving pSWE included 1527 patients, while nine studies involving 2-D SWE included 1088 patients. The areas under the summary receiver operating characteristic (SROC) curves for diagnosing significant fibrosis (F ≥ 2), advanced fibrosis (F ≥ 3), and cirrhosis (F = 4) using pSWE and 2-D SWE were as follows: 0.84 (95% CI 0.80-0.87), 0.91 (95% CI 0.88-0.93), and 0.94 (95% CI 0.91-0.95) for pSWE; 0.83 (95% CI 0.79-0.86) 0.85 (95% CI 0.82-0.88), and 0.89 (95% CI 0.86-0.91) for 2-D SWE, respectively. The pooled sensitivity for pSWE and 2-D SWE for stages F ≥ 2, F ≥ 3, and F = 4 were 0.71 (95% CI 0.63-0.78), 0.81 (95% CI 0.72-0.88), and 0.81 (95% CI 0.63-0.91) for pSWE, and 0.77 (95% CI 0.68-0.84), 0.80 (95% CI 0.72-0.87), and 0.92 (95% CI 0.75-0.98) for 2-D SWE, respectively. The pooled specificity of pSWE and 2-D SWE for these stages were 0.83 (95% CI 0.76-0.88), 0.87 (95% Cl: 0.81-0.92), and 0.91 (95% CI 0.86-0.94) for pSWE, and 0.76 (95% CI 0.66-0.84), 0.76 (95% CI 0.69-0.82), and 0.83 (95% CI 0.78-0.85) for 2-D SWE, respectively. In conclusion, both 2-D SWE and pSWE demonstrated high diagnostic performance in identifying various stages of liver fibrosis in MASLD patients.

摘要

为评估二维剪切波弹性成像(2-D SWE)和点剪切波弹性成像(pSWE)在检测代谢功能障碍相关脂肪性肝病(MASLD)患者肝纤维化分期中的诊断准确性,截至2024年2月9日,我们在四个数据库中进行了全面检索。采用双变量随机效应模型分析这些方法的诊断准确性。筛选后,13项涉及pSWE的研究纳入了1527例患者,而9项涉及2-D SWE的研究纳入了1088例患者。使用pSWE和2-D SWE诊断显著纤维化(F≥2)、进展性纤维化(F≥3)和肝硬化(F = 4)时,汇总受试者工作特征(SROC)曲线下面积如下:pSWE诊断显著纤维化、进展性纤维化和肝硬化时的曲线下面积分别为0.84(95%CI 0.80 - 0.87)、0.91(95%CI 0.88 - 0.93)和0.94(95%CI 0.91 - 0.95);2-D SWE诊断显著纤维化、进展性纤维化和肝硬化时的曲线下面积分别为0.83(95%CI 0.79 - 0.86)、0.85(95%CI 0.82 - 0.88)和0.89(95%CI 0.86 - 0.91)。pSWE和2-D SWE诊断F≥2、F≥3和F = 4期的汇总敏感度分别为:pSWE诊断F≥2期为0.71(95%CI 0.63 - 0.78),F≥3期为0.81(95%CI 0.72 - 0.88),F = 4期为0.81(95%CI 0.63 - 0.91);2-D SWE诊断F≥2期为0.77(95%CI 0.68 - 0.84),F≥3期为0.80(95%CI 0.72 - 0.87),F = 4期为0.92(95%CI 0.75 - 0.98)。pSWE和2-D SWE在这些分期中的汇总特异度分别为:pSWE诊断F≥2期为0.83(95%CI 0.76 - 0.88),F≥3期为0.87(95%CI 0.81 - 0.92),F = 4期为0.91(95%CI 0.86 - 0.94);2-D SWE诊断F≥2期为0.76(95%CI 0.66 - 0.84),F≥3期为0.76(95%CI 0.69 - 0.82),F = 4期为0.83(95%CI 0.78 - 0.85)。总之,2-D SWE和pSWE在识别MASLD患者肝纤维化的各个分期中均表现出较高的诊断性能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f645/11959393/24201bcb7503/bb-2024-11577f1.jpg

相似文献

5
Comparison of 2-D Shear Wave Elastography and Point Shear Wave Elastography for Assessing Liver Fibrosis.
Ultrasound Med Biol. 2021 Mar;47(3):408-427. doi: 10.1016/j.ultrasmedbio.2020.11.013. Epub 2020 Dec 17.

本文引用的文献

1
Epidemiology of metabolic dysfunction-associated steatotic liver disease.
Clin Mol Hepatol. 2025 Feb;31(Suppl):S32-S50. doi: 10.3350/cmh.2024.0431. Epub 2024 Aug 19.
2
Current status and future trends of the global burden of MASLD.
Trends Endocrinol Metab. 2024 Aug;35(8):697-707. doi: 10.1016/j.tem.2024.02.007. Epub 2024 Feb 29.
3
Up-to-date global epidemiology of nonalcoholic fatty liver disease.
Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):956-959. doi: 10.21037/hbsn-23-548. Epub 2023 Nov 9.
4
Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?
Intern Emerg Med. 2023 Oct;18(7):1887-1895. doi: 10.1007/s11739-023-03339-z. Epub 2023 Jul 25.
6
Comparison of strain elastography and shear wave elastography in diagnosis of fibrosis in nonalcoholic fatty liver disease.
J Med Ultrason (2001). 2023 Apr;50(2):187-195. doi: 10.1007/s10396-023-01293-z. Epub 2023 Feb 18.
7
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach.
Clin Mol Hepatol. 2022 Oct;28(4):841-850. doi: 10.3350/cmh.2022.0239. Epub 2022 Sep 19.
8
Comparing 2D-shear wave to transient elastography for the evaluation of liver fibrosis in nonalcoholic fatty liver disease.
Eur J Gastroenterol Hepatol. 2022 Sep 1;34(9):961-966. doi: 10.1097/MEG.0000000000002412. Epub 2022 Jul 19.
9
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0. Epub 2022 Jul 5.
10
Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients.
Clin Gastroenterol Hepatol. 2023 Apr;21(4):1013-1022.e6. doi: 10.1016/j.cgh.2022.05.015. Epub 2022 May 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验